At what enterprise value was BIOTEK INSTRUMENTS acquired in 2019?

During the acquisition of BIOTEK INSTRUMENTS by AGILENT TECHNOLOGIES in 2019, the transaction's Enterprise Value is estimated to be in the range of 1b - 4b USD.

What was the EV/EBITDA of BIOTEK INSTRUMENTS when it was acquired by AGILENT TECHNOLOGIES?

The estimated EV/EBITDA multiple for BIOTEK INSTRUMENTS is in the range of 15x - 25x.

When was BIOTEK INSTRUMENTS acquired by AGILENT TECHNOLOGIES?

BIOTEK INSTRUMENTS was acquired by AGILENT TECHNOLOGIES in 2019.

What was the EBITDA of BIOTEK INSTRUMENTS during the acquisition?

BIOTEK INSTRUMENTS's EBITDA is estimated to be in the range of 50M - 100M USD.

How is the data for the BIOTEK INSTRUMENTS acquisition sourced and is it reliable?

Mynth data is contributed by a professional community of M&A and Private Equity experts. Each transaction, including the BIOTEK INSTRUMENTS deal, is systematically cross-verified by our team using private deal documents and official sources. You can also find the official press release for this transaction here: https://www.investor.agilent.com/news-and-events/news/news-details/2019/Agilent-Completes-Acquisition-of-BioTek-Instruments/default.aspx

← DATABASE

Home Database Industry & ManufacturingBIOTEK INSTRUMENTS

08/2019

BIOTEK INSTRUMENTS acquired by AGILENT TECHNOLOGIES

UNITED STATES Industrial Equipment / Special Machinery / Lab & Scientific Equipment EV 1b - 4b USD

Context

Agilent has finalized the acquisition of BioTek Instruments in an all-cash transaction, a maneuver designed to fundamentally expand its capabilities in the critical cell analysis technology sector. The strategic rationale for this transaction centers on a "workflow-simplification" play, merging the target's industry-leading expertise in microplate detection and imaging with the group’s established presence in live-cell, real-time analysis. This structural alignment provides the organization with the scientific talent and technological hardware required to address the increasing complexity of immunotherapy and biologics research. This operation allows the group to execute a definitive structural expansion of its biopharma and academic service offerings.

BIOTEK INSTRUMENTS, which reported an EBITDA margin of in 2019, is valued in this transaction at an EV/EBITDA multiple of , representing a to the average currently observed in the Industry & Manufacturing sector (11.8x).

-> Deep-dive in Industry & Manufacturing market trends

Target

BioTek Instruments is a USA company specialized in Life Science Instrumentation. They are recognized as a leader in the design and manufacture of innovative microplate instrumentation and software that allow scientists to visualize and quantify cellular interactions. Instead of offering generic lab tools, they thrive on a philosophy of technical precision, providing high-performance imaging and multi-mode detection systems that are critical for drug discovery and immunotherapy research. What makes them a go-to partner is their knack for integrating complex imaging software with automated hardware, helping academic and biopharma researchers obtain deep insights into complex cellular environments.

Ent. Value

Equity Value

Multiples

EV / Revenue

EV / EBITDA

EV / EBIT

Historical Financials (USD)

Year

Rev

EBITDA

EBIT

2019

2018

Similar deals in Industrial Equipment

List of similar M&A transactions (Date, Acquirer, Target, Country, Sub-sector)
Date	Acquirer	Target	Country	Sector
09/2019	CAPITAL EXPORT	REPACK-S	FRANCE	Valves, Pumps & Taps
09/2019	VOITH GROUP	BTG	SWITZERLAND	Instrumentation & Measurement
08/2019	TELEDYNE TECHNOLOGIES INCORPORATED	3M GAS AND FLAME DETECTION	FRANCE	Instrumentation & Measurement
02/2019	DANAHER	GE LIFE SCIENCES	UNITED STATES	Lab & Scientific Equipment
01/2019	ARDIAN	CELLI GROUP	ITALY	Food & Beverage Lines
12/2018	HITACHI	ABB Power Grids	SWITZERLAND	Electrical Equipment
09/2018	GROUPE ATLANTIC	ACV	BELGIUM	Boilers & Thermal Solutions
07/2018	WEIR GROUP	ESCO CORPORATION	UNITED STATES	Special Machinery
07/2018	TSINGHUA UNIGROUP	LINXENS	FRANCE	Safety & Security
07/2018	MAREL	MAJA	GERMANY	Food & Beverage Lines

REFERENCES

Valuation range: EV 1b - 4b USD

EBITDA range: 50M - 100M USD

Note: This page provides detailed data on a private equity M&A transaction. Detailed and exact financial metrics for the acquisition of BIOTEK INSTRUMENTS by AGILENT TECHNOLOGIES are reserved for mynth community members. Register for free to unlock full data.

Authors: This transaction was contributed by a verified mynth contributor and cross-checked against available transaction documents and official company communications.

Press release: view release

Acquirer: agilent technologies